キネレット皮下注 100 mg シリンジ

＜アナキンラ（遺伝子組換え）＞

第 2 部（モジュール 2）
CTD の概要（サマリー）

2.7　臨床概要

2.7.5　参考文献

Swedish Orphan Biovitrum Japan 株式会社

Property of the SOBI group - strictly confidential

目次

2.7.5 参考文献 3

2.7.5 参考文献

Ahmed O, Brahmania M, Alsahafi M, Alkhowaiter S, Erb S. Anakinra hepatotoxicity in a patient with adult-onset Still's disease. ACG Case Rep J. 2015;2(3):173-174.

Alpay N, Sumnu A, Çalışkan Y, Yazıcı H, Türkmen A, Gül A. Efficacy of anakinra treatment in a patient with colchicine-resistant familial Mediterranean fever. Rheumatol Int. 2012;32(10):3277-3279.

Beukelman T, Xie F, Chen L, Baddley JW, Delzell E, Grijalva CG, et al. Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum. 2012;64(8):2773-2780.

Cavalli G, Franchini S, Berti A, Campochiaro C, Guglielmi B, Sabbadini MG, et al. Efficacy and safety of biologic agents in adult-onset Still's disease: A long-term follow-up of 19 patients at a single referral center. Abstr. 2028 Am. Coll. Rheumatol. Annu. Meet.

Cavalli G, Franchini S, Aiello P, Guglielmi B, Berti A, Campochiaro C, et al. Efficacy and safety of biological agents in adult-onset Still's disease. Scand J Rheumatol. 2015;44(4):309-314.

Colafrancesco S, Priori R, Valesini G, Argolini L, Baldissera E, Bartoloni E, et al. Response to Interleukin-1 Inhibitors in 140 Italian Patients with Adult-Onset Still's Disease: A Multicentre Retrospective Observational Study. Front Pharmacol. 2017;8:369.

Dall'Ara F, Frassi M, Tincani A, Airò P. A retrospective study of patients with adult-onset Still's disease: is pericarditis a possible predictor for biological disease-modifying anti-rheumatic drugs need? Clin Rheumatol. 2016;35(8):2117-2123.

Debiais, S, F Maillot, L Luca, J Buret, B Fautrel, JP Renard. Efficacy of anakinra in a case of refractory still disease. J Clin Rheumatol. 2008;14(6):357-358.

DeWitt EM, Kimura Y, Beukelman T, Nigrovic PA, Onel K, Prahalad S, et al. Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2012;64(7):1001-1010.

Emmanouel DS, Lindheimer MD, Katz AI. Role of the kidney in hormone metabolism and its implications in clinical medicine. Klin Wochenschr. 1980; 58 (19):1005-1012.

Eriksson P, Jacobs C, Söderkvist P. A patient with a phenotype of adult-onset still disease, but a genotype typical of cryopyrin-associated periodic fever syndrome. J Rheumatol. 2013;40(9):1632-1633.

Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum. 1993;36(6):729-740.

Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995;38(6):727–735.

Fitzgerald AA, Leclercq SA, Yan A, Homik JE, Dinarello CA. Rapid responses to anakinra in patients with refractory adult-onset Still's disease. Arthritis Rheum. 2005;52(6):1794-1803.

Galea J, Ogungbenro K, Hulme S, Greenhalgh A, Aarons L, Scarth S, et al. Intravenous anakinra can achieve experimentally effective concentrations in the central nervous system within a therapeutic time window: Results of a dose-ranging study. J Cereb Blood Flow Metab. 2011;31(2):439-447.

Gattorno M, Piccini A, Lasigliè D, Tassi S, Brisca G, Carta S, et al. The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2008;58(5):1505-1515.

Gerfaud-Valentin M, Maucort-Boulch D, Hot A, Iwaz J, Ninet J, Durieu I, et al. Adult-onset still disease: manifestations, treatment, outcome, and prognostic factors in 57 patients. Medicine (Baltimore). 2014;93(2):91-99.

Giampietro C, Ridene M, Fautrel B, Bourgeois P. Long term treatment with anakinra in patients with adult-onset Still disease. Arthritis Rheum. 2010;62(Suppl 10): 902.

Giampietro C, Ridene M, Lequerre T, Costedoat Chalumeau N, Amoura Z, Sellam J, et al. Anakinra in adult-onset Still's disease: Long-term treatment in patients resistant to conventional therapy. Arthritis Care Res (Hoboken). 2013;65(5):822-826.

Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum. 1997;40(7):1202-1209.

Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York, NY: Marcel Dekker, Inc. 1982.

Granowitz EV, Porat R, Mier JW, Pribble JP, Stiles DM, Bloedow DC, et al. Pharmacokinetics, safety and immunomodulatory effects of human recombinant interleukin-1 receptor antagonist in healthy humans. Cytokine. 1992;4(5):353-360.

Hartig I, Schroeder JO, Mrowietz U. Neutrophilic urticarial dermatosis (NUD) in probable adult-onset still disease responding to anakinra. J Clin Rheumatol. 2014;20(2):96-98.

Hedrich CM, Bruck N, Fiebig B, Gahr M. Anakinra: A safe and effective first-line treatment in systemic onset juvenile idiopathic arthritis (SoJIA). Rheumatol Int. 2012;32(11):3525-3530.

Hong D, Yang Z, Han S, Liang X, Ma K, Zhang X. Interleukin 1 inhibition with anakinra in adult-onset still disease: A meta-analysis of its efficacy and safety. Drug Des Devel Ther. 2014 Nov 25;8:2345-2357.

Iliou C, Papagoras C, Tsifetaki N, Voulgari PV, Drosos AA. Adult-onset Still's disease: Clinical, serological and therapeutic considerations. Clin Exp Rheumatol. 2013;31(1):47-52.

Ilowite N, Porras O, Reiff A, Rudge S, Punaro M, Martin A, et al. Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: Safety and preliminary efficacy results of a randomized multicenter study. Clin Rheumatol. 2009;28(2):129-137.

Jamilloux Y, Gerfaud-Valentin M, Martinon F, Belot A, Henry T, Sève P. Pathogenesis of adult-onset Still's disease: New insights from the juvenile counterpart. Immunol Res. 2015;61(1-2):53-62.

Kearsley-Fleet L, Beresford MW, Davies R, De Cock D, Baildam E, Foster HE, et al. Short-term outcomes in patients with systemic juvenile idiopathic arthritis treated with either tocilizumab or anakinra. Rheumatology (Oxford). 2019;58(1):94-102.

Kimura Y, DeWitt EM, Beukelman T, Stoll ML, Nigrovic PA, Onel K, et al. Adding canakinumab to the childhood arthritis and rheumatology research alliance consensus treatment plans for systemic juvenile idiopathic arthritis: Comment on the article by DeWitt et al. Arthritis Care Res (Hoboken). 2014;66(9):1430-1431.

Laskari K, Tzioufas AG, Moutsopoulos HM. Efficacy and long-term follow-up of IL-1R inhibitor anakinra in adults with Still's disease: A case-series study. Arthritis Res Ther. 2011;13(3):R91.

Lequerré T, Quartier P, Rosellini D, Alaoui F, De Bandt M, Mejjad O, et al. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset still disease: Preliminary experience in France. Ann Rheum Dis. 2008;67(3):302-308.

Maack T, Johnson V, Kau ST, Figueiredo J, Sigulem D. Renal filtration, transport, and metabolism of low-molecular-weight proteins: a review. Kidney Int. 1979 Sep; 16 (3):251-270.

Maier J, Birkenfeld G, Pfirstinger J, Schölmerich J, Fleck M, Brühl H. Effective treatment of steroid refractory adult-onset Still's disease with anakinra. J Rheumatol. 2008;35(5):939-941.

Naumann L, Feist E, Natusch A, Langen S, Krause A, Buttgereit F, et al. IL1-receptor antagonist anakinra provides long-lasting efficacy in the treatment of refractory adult-onset Still's disease. Ann Rheum Dis. 2010;69(2):466-467.

Nielsen JT. Handling of proteins in isolated and in vitro perfused proximal tubules from rabbit kidney. Dan Med Bull. 1990; 37:197-210.

Nigrovic PA, Mannion M, Prince FH, Zeft A, Rabinovich CE, van Rossum MA, et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: Report of fortysix patients from an international multicenter series. Arthritis Rheum. 2011;63(2):545-555.

Nordström D, Knight A, Luukkainen R, van Vollenhoven R, Rantalaiho V, Kajalainen A, et al. Beneficial effect of interleukin 1 inhibition with anakinra in adult-onset Still's disease. An open, randomized, multicenter study. J Rheumatol. 2012;39(10):2008-2011.

Ortiz-Sanjuán F, Blanco R, Riancho-Zarrabeitia L, Castañeda S, Olivé A, Riveros A, et al. Efficacy of anakinra in refractory adult-onset Still's disease: Multicenter study of 41 patients and literature review. Medicine (Baltimore). 2015;94(39):e1554.

Pardeo M, Pires Marafon D, Insalaco A, Bracaglia C, Nicolai R, Messia V, et al. Anakinra in systemic juvenile idiopathic arthritis: A single-center experience. J Rheumatol. 2015;42(8):1523-1527.

Pascual V, Allantaz F, Arce E, Punaro M, Banchereau J. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med. 2005;201(9):1479-1486.

Petty RE, Southwood TR, Baum J, Bhettay E, Glass DN, Manners P, et al. Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997. J Rheumatol. 1998;25(10):1991-1994.

Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International league of associations for rheumatology classification of juvenile idiopathic arthritis: Second revision, edmonton, 2001. J Rheumatol. 2004;31(2):390-392.

Pihl S, Michaut L, Hendriks J, Loebbert R, Ryding J, Nemansky M, et al. EBF recommendation for stability testing of anti-drug antibodies; lessons learned from anti-vaccine antibody stability studies. Bioanalysis. 2014;6(10):1409-1413.

Priori R, Ceccarelli F, Barone F, Iagnocco A, Valesini G. Clinical, biological and sonographic response to IL-1 blockade in adult-onset Still's disease. Clin Exp Rheumatol. 2008;26(5):933-937.

Quartier P, Allantaz F, Cimaz R, Pillet P, Messiaen C, Bardin C, et al. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis. 2011;70(5):747-754.

Ravelli A, Davì S, Minoia F, Martini A, Cron RQ. Macrophage activation syndrome. Hematol Oncol Clin North Am. 2015;29(5):927-941.

Riera E, Olivé A, Narváez J, Holgado S, Santo P, Mateo L, et al. Adult onset Still's disease: review of 41 cases. Clin Exp Rheumatol. 2011;29(2):331-336.

Rossi-Semerano L, Fautrel B, Wendling D, Hachulla E, Galeotti C, Semerano L, et al. Tolerance and efficacy of off-label anti-interleukin-1 treatments in France: A nationwide survey. Orphanet J Rare Dis. 2015;10:19.

Ruperto N, Ravelli A, Falcini F, Lepore L, De Sanctis R, Zulian F, et al. Performance of the preliminary definition of improvement in juvenile chronic arthritis patients treated with methotrexate. Italian Pediatric Rheumatology Study Group. Ann Rheum Dis. 1998;57:38-41.

Saccomanno B, Tibaldi J, Minoia F, Bagnasco F, Pistorio A, Guariento A, et al. Predictors of Effectiveness of Anakinra in Systemic Juvenile Idiopathic Arthritis. J Rheumatol. 2019;46(4):416-421.

Sfriso P, Priori R, Valesini G, Rossi S, Montecucco CM, D'Ascanio A, et al. Adult-onset Still's disease: an Italian multicentre retrospective observational study of manifestations and treatments in 245 patients. Clin Rheumatol. 2016;35(7):1683-1689.

Singh N, Hopkins SJ, Hulme S, Galea JP, Hoadley M, Vail A, et al. The effect of intravenous interleukin-1 receptor antagonist on inflammatory mediators in cerebrospinal fluid after subarachnoid haemorrhage: A phase II randomised controlled trial. J Neuroinflammation. 2014;11:1.

Ter Haar NM, van Dijkhuizen EHP, Swart JF, van Royen-Kerkhof A, El Idrissi A, Leek AP, et al. Treatment to target using recombinant interleukin-1 receptor antagonist as first-line monotherapy in new-onset systemic juvenile idiopathic arthritis: Results from a Five-Year Follow-Up Study. Arthritis Rheumatol. 2019;71(7):1163-1173.

Topaloglu R, Batu ED, Orhan D, Ozen S, Besbas N. Anti-interleukin 1 treatment in secondary amyloidosis associated with autoinflammatory diseases. Pediatr Nephrol. 2016;31(4):633-640.

Urien S, Bardin C, Bader-Meunier B, Mouy R, Compeyrot-Lacassagne S, Foissac F, et al. Anakinra pharmacokinetics in children and adolescents with systemic-onset juvenile idiopathic arthritis and autoinflammatory syndromes. BMC Pharmacol Toxicol. 2013;14-40.

Vastert SJ, de Jager W, Noordman BJ, Holzinger D, Kuis W, Prakken BJ, et al. Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: Results of a prospective cohort study. Arthritis Rheumatol. 2014;66(4):1034-1043.

Verbsky JW, White AJ. Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis. J Rheumatol. 2004;31(10):2071-2075.

Vercoutere W, Starmans-Kool M, Peeters RM. [Anakinra in refractory adult onset Still's disease]. Ned Tijdschr Geneeskd. 2011;155(18):A2966.

Vercruysse F, Barnetche T, Lazaro E, Shipley E, Lifermann F, Balageas A, et al. Adult-onset Still's disease biological treatment strategy may depend on the phenotypic dichotomy. Arthritis Res Ther. 2019;21(1):53.

Vordenbäumen S, Ostendorf B, Sander O, Richter J, Schneider M. Continuation of anakinra despite the development of a pruritic rash in an otherwise refractory case of adult-onset Still's disease. Ann Rheum Dis. 2009;68(3):450-451.

Wallace CA, Giannini EH, Huang B, Itert L, Ruperto N. American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis. Arthritis Care Res. 2011;63(7):929-936.

Yamaguchi M, Ohta A, Tsunematsu T, Kasukawa R, Mizushima Y, Kashiwagi H, et al. Preliminary criteria for classification of adult Still's disease. J Rheumatol. 1992;19(3):424-430.

Yang B, Baughman S, Frazier J, Hollifield A, Yates W, Lescale-Matys L, Sullivan JT, et al. Pharmacokinetics (PK) of Anakinra in Subjects With Various Degrees of Renal Function. Clin Pharmacol Ther. 2002;71:P14. Abstract. (M5.3.3.3.1 20000268 Appendix 17)

Yang B, Baughman S, Sullivan JT. The Kidney is the Major Organ of Elimination of Kineret™ (anakinra) [abstract]. To be presented at the European League Against Rheumatism Annual Meeting on 12 to 15 June 2002 in Stockholm, Sweden. (M5.3.3.3.1 20000268 Appendix 17)

Yang BB, Baughman S, Sullivan JT. Pharmacokinetics of anakinra in subjects with different levels of renal function. Clin Pharmacol Ther. 2003;74(1):85-94.

Yap SH, Moshage HJ, Hazenberg BP, Roelofs HM, Bijzet J, Limburg PC, et al. Tumor necrosis factor (tnf) inhibits interleukin (il)-1 and/or il-6 stimulated synthesis of c-reactive protein (crp) and serum amyloid a (saa) in primary cultures of human hepatocytes. Biochim Biophys Acta. 1991;1091(3):405-408.

Yilmaz S, Cinar M, Simsek I, Erdem H, Pay S. Long-term efficacy and safety of anakinra in a patient with liver transplant due to adult onset Still's disease. Mod Rheumatol. 2014;24(6):1030-1031.

Yoshizaki K. Pathogenic role of IL-6 combined with TNF-α or IL-1 in the induction of acute phase proteins SAA and CRP in chronic inflammatory diseases. Adv Exp Med Biol. 2011;691:141-150.

Zeft A, Hollister R, LaFleur B, Sampath P, Soep J, McNally B, et al. Anakinra for systemic juvenile arthritis: The rocky mountain experience. J Clin Rheumatol. 2009;15(4):161-164.

Kineret 欧州製品概要